DUBLIN, Ireland, May 11, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it will host a symposium to present expanded pivotal safety and efficacy data for NV-01 (ranevetmab), a novel caninized anti-nerve growth factor (NGF) monoclonal antibody (mAb) under clinical investigation for the control of pain associated with osteoarthritis in dogs, and the latest clinical data for NV-02, the analogous felinized mAb for cats, at the ACVIM Forum in Denver, Colorado, on June 9th, 2016. In addition, Nexvet clinical collaborator Dr. Margaret Gruen of North Carolina State University’s Comparative Pain Research Program will present an extended clinical research abstract at ACVIM relating to Nexvet’s proof-of-concept efficacy study of NV-02 entitled “Feline Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain” at 9AM UTC on June 11th.
The Company’s seminar on June 9th at 6:30AM - 8:30AM UTC will showcase the underlying biology of NGF, clinical study design of its chronic pain programs, as well as provide an update on ranevetmab’s pivotal safety and efficacy data in dogs with osteoarthritis. This study was announced to have met its primary efficacy endpoint (p ≤0.038) in November 2015. Professor Duncan Lascelles of North Carolina State University’s Comparative Pain Research Program, a leader in veterinary and comparative pain management, will be the featured speaker, providing the context for chronic pain in dogs and cats, including its measurement and unmet needs. Nexvet speakers will include: Dr Juergen Horn, Chief Product Development Officer, Dr. Colin Giles, Vice President, Clinical and Regulatory, and Dr. Jane Eagleson, Director of Clinical and Regulatory Affairs.
“As a company with programs in late-stage clinical development, we will increasingly utilize premier veterinary specialist conferences to engage with key opinion leaders and practicing veterinarians about biologics and Nexvet’s product candidates. Our market surveys have unequivocally demonstrated that a monthly subcutaneous injection for chronic pain indications in both dogs and cats is a very attractive concept and would be welcomed by veterinarians. mAbs targeting NGF are an entirely novel modality for veterinary pain management and are based on substantial validation from human clinical trials, validation we are the first to demonstrate from pivotal companion animal studies,” commented Dr. Mark Heffernan, Chief Executive Officer of Nexvet.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements consist of all statements other than statements of historical fact, including statements regarding our future results of operations and financial position, results of any current or future pivotal safety and efficacy study, future expenditures relating to our lead product candidates, time for completion of any of our studies or facilities updates, ability to develop our pipeline of product candidates, business strategy, prospective products, ability to successfully manufacture our own product candidates, ability to meet conditions for the receipt of government grants, ability to qualify for conditional licensure or obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “position,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors.
Factors that could cause actual results to differ materially from our expectations expressed in this report include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 firstname.lastname@example.org Media Jessica Burns Berry & Company Public Relations +1 212-253-8881 email@example.com
Source:Nexvet Biopharma plc